Huo, G., Huo, G., Huo, G., Huo, G., Song, Y., Liu, W., . . . Chen, P. (2024). Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer. Frontiers Media S.A.
Citación estilo ChicagoHuo, Gengwei, et al. Cost-effectiveness of Dostarlimab Plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer. Frontiers Media S.A, 2024.
Cita MLAHuo, Gengwei, et al. Cost-effectiveness of Dostarlimab Plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer. Frontiers Media S.A, 2024.
Warning: These citations may not always be 100% accurate.